Apellis reports PhII ALS fail after stopping open-label extension in April
Apellis and Sobi will discontinue development in ALS after their approved rare blood and eye disease drug failed a Phase II study.
The pair was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
